Oncogenic HER2{Delta}16 Suppresses MiR-15a/16 and Deregulates BCL-2 to Promote Endocrine Resistance of Breast Tumors

Overview

Journal Carcinogenesis

Specialty Oncology

Date 2010 Sep 30

PMID 20876285

Citations 87

Authors

Diana M Cittelly

Partha M Das

Virgilio A Salvo

Juan P Fonseca

Matthew E Burow

Frank E Jones

Affiliations

Soon will be listed here.

Abstract

Tamoxifen is the most commonly prescribed therapy for patients with estrogen receptor (ER)α-positive breast tumors. Tumor resistance to tamoxifen remains a serious clinical problem especially in patients with tumors that also overexpress human epidermal growth factor receptor 2 (HER2). Current preclinical models of HER2 overexpression fail to recapitulate the clinical spectrum of endocrine resistance associated with HER2/ER-positive tumors. Here, we show that ectopic expression of a clinically important oncogenic isoform of HER2, HER2Δ16, which is expressed in >30% of ER-positive breast tumors, promotes tamoxifen resistance and estrogen independence of MCF-7 xenografts. MCF-7/HER2Δ16 cells evade tamoxifen through upregulation of BCL-2, whereas mediated suppression of BCL-2 expression or treatment of MCF-7/HER2Δ16 cells with the BCL-2 family pharmacological inhibitor ABT-737 restores tamoxifen sensitivity. Tamoxifen-resistant MCF-7/HER2Δ16 cells upregulate BCL-2 protein levels in response to suppressed ERα signaling mediated by estrogen withdrawal, tamoxifen treatment or fulvestrant treatment. In addition, HER2Δ16 expression results in suppression of BCL-2-targeting microRNAs miR-15a and miR-16. Reintroduction of miR-15a/16 reduced tamoxifen-induced BCL-2 expression and sensitized MCF-7/HER2Δ16 to tamoxifen. Conversely, inhibition of miR-15a/16 in tamoxifen-sensitive cells activated BCL-2 expression and promoted tamoxifen resistance. Our results suggest that HER2Δ16 expression promotes endocrine-resistant HER2/ERα-positive breast tumors and in contrast to wild-type HER2, preclinical models of HER2Δ16 overexpression recapitulate multiple phenotypes of endocrine-resistant human breast tumors. The mechanism of HER2Δ16 therapeutic evasion, involving tamoxifen-induced upregulation of BCL-2 and suppression of miR-15a/16, provides a template for unique therapeutic interventions combining tamoxifen with modulation of microRNAs and/or ABT-737-mediated BCL-2 inhibition and apoptosis.

Citing Articles

Exosomal microRNA as a key regulator of PI3K/AKT pathways in human tumors.

Jasim S, Ahmed A, Kubaev A, Kyada A, Alshahrani M, Sharma S Med Oncol. 2024; 41(11):265.

PMID: 39400677 DOI: 10.1007/s12032-024-02529-9.

Examining the evidence for mutual modulation between m6A modification and circular RNAs: current knowledge and future prospects.

Tang X, Guo M, Zhang Y, Lv J, Gu C, Yang Y J Exp Clin Cancer Res. 2024; 43(1):216.

PMID: 39095902 PMC: 11297759. DOI: 10.1186/s13046-024-03136-2.

Non-Coding RNAs Modulating Estrogen Signaling and Response to Endocrine Therapy in Breast Cancer.

Treeck O, Haerteis S, Ortmann O Cancers (Basel). 2023; 15(6).

PMID: 36980520 PMC: 10046587. DOI: 10.3390/cancers15061632.

Mutual regulation between N6-methyladenosine (m6A) modification and circular RNAs in cancer: impacts on therapeutic resistance.

Lin H, Wang Y, Wang P, Long F, Wang T Mol Cancer. 2022; 21(1):148.

PMID: 35843942 PMC: 9290271. DOI: 10.1186/s12943-022-01620-x.

Tumour suppressor microRNAs contribute to drug resistance in malignant pleural mesothelioma by targeting anti-apoptotic pathways.

Williams M, Cheng Y, Phimmachanh M, Winata P, van Zandwijk N, Reid G Cancer Drug Resist. 2022; 2(4):1193-1206.

PMID: 35582270 PMC: 9019216. DOI: 10.20517/cdr.2019.41.

References

Cannings E, Kirkegaard T, Tovey S, Dunne B, Cooke T, Bartlett J . Bad expression predicts outcome in patients treated with tamoxifen. Breast Cancer Res Treat. 2006; 102(2):173-9. DOI: 10.1007/s10549-006-9323-8. View

Naresh A, Thor A, Edgerton S, Torkko K, Kumar R, Jones F . The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis. Cancer Res. 2008; 68(15):6387-95. PMC: 2538429. DOI: 10.1158/0008-5472.CAN-08-0538. View

Henriksen K, Rasmussen B, Lykkesfeldt A, Moller S, Ejlertsen B, Mouridsen H . An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer. Acta Oncol. 2009; 48(4):522-31. DOI: 10.1080/02841860802676383. View

Massarweh S, Osborne C, Creighton C, Qin L, Tsimelzon A, Huang S . Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res. 2008; 68(3):826-33. DOI: 10.1158/0008-5472.CAN-07-2707. View

Esquela-Kerscher A, Slack F . Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006; 6(4):259-69. DOI: 10.1038/nrc1840. View

Planas-Silva M, Bruggeman R, Grenko R, Smith J . Overexpression of c-Myc and Bcl-2 during progression and distant metastasis of hormone-treated breast cancer. Exp Mol Pathol. 2006; 82(1):85-90. DOI: 10.1016/j.yexmp.2006.09.001. View

Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, Letai A . BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell. 2007; 12(2):171-85. DOI: 10.1016/j.ccr.2007.07.001. View

Zhang G, Kimijima I, Onda M, Kanno M, Sato H, Watanabe T . Tamoxifen-induced apoptosis in breast cancer cells relates to down-regulation of bcl-2, but not bax and bcl-X(L), without alteration of p53 protein levels. Clin Cancer Res. 1999; 5(10):2971-7. View

Kurokawa H, Lenferink A, Simpson J, Pisacane P, Sliwkowski M, Forbes J . Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res. 2000; 60(20):5887-94. View

10.

Siegel P, Ryan E, Cardiff R, Muller W . Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J. 1999; 18(8):2149-64. PMC: 1171299. DOI: 10.1093/emboj/18.8.2149. View

11.

Fabbri M, Croce C, Calin G . MicroRNAs. Cancer J. 2008; 14(1):1-6. DOI: 10.1097/PPO.0b013e318164145e. View

12.

Cimmino A, Calin G, Fabbri M, Iorio M, Ferracin M, Shimizu M . miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005; 102(39):13944-9. PMC: 1236577. DOI: 10.1073/pnas.0506654102. View

13.

Verghese E, Hanby A, Speirs V, Hughes T . Small is beautiful: microRNAs and breast cancer-where are we now?. J Pathol. 2008; 215(3):214-21. DOI: 10.1002/path.2359. View

14.

Miller T, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro C . MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem. 2008; 283(44):29897-903. PMC: 2573063. DOI: 10.1074/jbc.M804612200. View

15.

Mitra D, Brumlik M, Okamgba S, Zhu Y, Duplessis T, Parvani J . An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance. Mol Cancer Ther. 2009; 8(8):2152-62. DOI: 10.1158/1535-7163.MCT-09-0295. View

16.

Thiantanawat A, Long B, Brodie A . Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens. Cancer Res. 2003; 63(22):8037-50. View

17.

Osborne C, Schiff R . Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol. 2005; 23(8):1616-22. DOI: 10.1200/JCO.2005.10.036. View

18.

Wickramasinghe N, Manavalan T, Dougherty S, Riggs K, Li Y, Klinge C . Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells. Nucleic Acids Res. 2009; 37(8):2584-95. PMC: 2677875. DOI: 10.1093/nar/gkp117. View

19.

Wang L, Yang X, Zhang X, An P, Kim H, Huang J . Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer. Cancer Cell. 2006; 10(6):487-99. DOI: 10.1016/j.ccr.2006.09.015. View

20.

Benz C, Scott G, Sarup J, Johnson R, Tripathy D, Coronado E . Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat. 1993; 24(2):85-95. DOI: 10.1007/BF01961241. View